Great Point Partners LLC
- SEC CIK
- 0001281446
- Latest filing
- Aug 14, 2026
Holdings in Q1 2024
Holdings as of Mar 31, 2024, filed May 15, 2024. Long positions only; changes compare share counts with Q4 2023.
- Positions
- 35
- +1 vs. Q4 2023
- Portfolio value
- $641.6M
- +$54.9M (+9.4%) vs. Q4 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| NGNENeurogene Inc. | COM | 1,004,291 | $51.1M | 8.0% | +10,062+1.0% | Added | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 1,128,499 | $44.7M | 7.0% | −2,574,934−69.5% | Reduced | History |
| URGNUroGen Pharma Ltd. | COM | 2,620,545 | $39.3M | 6.1% | 00.0% | Unchanged | History |
| ABVXAbivax S.A. | SPONSORED ADS | 2,488,483 | $35.6M | 5.5% | +938,483+60.5% | Added | History |
| EOLSEvolus, Inc. | COM | 2,450,000 | $34.3M | 5.3% | +450,000+22.5% | Added | History |
| PLRXPliant Therapeutics, Inc. | COM | 1,851,864 | $27.6M | 4.3% | +28,680+1.6% | Added | History |
| APGEApogee Therapeutics, Inc. | COM | 400,000 | $26.6M | 4.1% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM | 887,690 | $26.2M | 4.1% | −150,000−14.5% | Reduced | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,335,000 | $23.4M | 3.6% | +1,335,000 | New | History |
| ANABAnaptysbio, Inc | COM | 976,981 | $22.0M | 3.4% | 00.0% | Unchanged | History |
| ESPREsperion Therapeutics, Inc. | COM | 8,000,000 | $21.4M | 3.3% | +8,000,000 | New | History |
| INSMINSMED Inc | COM PAR $.01 | 775,585 | $21.0M | 3.3% | +549,673+243.3% | Added | History |
| ACLXArcellx, Inc. | COMMON STOCK | 300,000 | $20.9M | 3.3% | +251,736+521.6% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 456,148 | $19.6M | 3.1% | −143,852−24.0% | Reduced | History |
| DFTXDefinium Therapeutics, Inc. | Stock | 2,000,000 | $18.8M | 2.9% | +2,000,000 | New | History |
| DNTHDianthus Therapeutics, Inc. | COM | 625,000 | $18.8M | 2.9% | +625,000 | New | History |
| OTLKOutlook Therapeutics, Inc. | Stock | 1,480,000 | $17.7M | 2.8% | +1,480,000 | New | History |
| FOLDAmicus Therapeutics, Inc. | COM | 1,495,500 | $17.6M | 2.7% | +215,000+16.8% | Added | History |
| OCULOcular Therapeutix, Inc | COM | 1,728,723 | $15.7M | 2.5% | +1,028,723+147.0% | Added | History |
| DVAXDynavax Technologies Corp | COM NEW | 1,264,920 | $15.7M | 2.4% | +1,264,920 | New | History |
| CYTKCytokinetics Inc | COM NEW | 202,202 | $14.2M | 2.2% | −297,798−59.6% | Reduced | History |
| OPTNOptiNose, Inc. | COM | 8,786,318 | $12.8M | 2.0% | −53,621−0.6% | Reduced | History |
| JSPRJasper Therapeutics, Inc. | COM NEW | 407,550 | $12.0M | 1.9% | +407,550 | New | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 150,000 | $10.4M | 1.6% | +39,393+35.6% | Added | History |
| MRUSMerus N.V. | COM | 223,288 | $10.1M | 1.6% | +203,288+1,016.4% | Added | History |
| VTGNVistagen Therapeutics, Inc. | COM | 1,858,735 | $9.81M | 1.5% | 00.0% | Unchanged | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 1,309,975 | $8.59M | 1.3% | 00.0% | Unchanged | History |
| IMCRImmunocore Holdings plc | ADS | 115,000 | $7.47M | 1.2% | −178,000−60.8% | Reduced | History |
| AUTLAutolus Therapeutics plc | SPON ADS | 1,166,667 | $7.44M | 1.2% | +1,166,667 | New | History |
| PBYIPuma Biotechnology, Inc. | COM | 1,343,628 | $7.12M | 1.1% | +250,355+22.9% | Added | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 2,757,740 | $7.09M | 1.1% | −537,260−16.3% | Reduced | History |
| BBOTBridgeBio Oncology Therapeutics, Inc. | CL A ORD SHS | 500,000 | $5.20M | 0.8% | +500,000 | New | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 125,000 | $4.74M | 0.7% | 00.0% | Unchanged | History |
| KYTXKyverna Therapeutics, Inc. | COM | 150,000 | $3.73M | 0.6% | +150,000 | New | History |
| ARVNArvinas, Inc. | COM | 71,113 | $2.94M | 0.5% | −162,969−69.6% | Reduced | History |
Sold out since Q4 2023 (9)
Positions held at the end of Q4 2023 that are gone from this filing.
| Security | Class | Shares in Q4 2023 | Value in Q4 2023 | % of portfolio in Q4 2023 | History |
|---|---|---|---|---|---|
| RAREUltragenyx Pharmaceutical Inc. | COM | 648,000 | $31.0M | 5.3% | History |
| RAPTRAPT Therapeutics, Inc. | COM | 1,099,753 | $27.3M | 4.7% | History |
| ALKSAlkermes plc. | SHS | 875,044 | $24.3M | 4.1% | History |
| PCVXVaxcyte, Inc. | COM | 360,000 | $22.6M | 3.9% | History |
| TRMLTourmaline Bio, Inc. | COM | 672,885 | $17.6M | 3.0% | History |
| KRTXKaruna Therapeutics, Inc. | COM | 30,250 | $9.57M | 1.6% | History |
| SRPTSarepta Therapeutics, Inc. | COM | 80,000 | $7.71M | 1.3% | History |
| AXSMAxsome Therapeutics, Inc. | COM | 4,963 | $395.0K | 0.1% | History |
| MURAMural Oncology plc | ORD SHS | 11,509 | $68.1K | <0.1% | History |